However, FGFR2 gene amplification or point mutation were found in only 24 out of 1636 (1.47%) invasive ductal carcinoma of no special type (IDC, NST) patients and had no effect on overall survival (log-rank p = 0.170). Here, FGFR2 is linked to invasive ductal breast carcinoma.